NVO News and Press, Novo Nordisk A/S From 06/27/24

2024-06-27 06:56:19 ET More on Novo Nordisk Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk hypertensio...

2024-06-26 13:12:43 ET More on Novo Nordisk Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It GLP-1 weight loss meds +...

2024-06-26 12:31:01 ET Volume away from semiconductor ETFs’ ( SMH ), ( SEMI ), ( NASDAQ: SOXX ) overbought conditions could mean some long-term bullishness with other parts of the market seeing gains, according to an Argus Research Market Movers note.... Read th...

2024-06-26 07:00:00 ET Summary Novo Nordisk gains approval in China for blockbuster drug Wegovy. More than 11% of all adults in China live with diabetes - more than any other country in the world. Both Eli Lilly and Novo Nordisk are disrupting the diet industry with their GLP-...

2024-06-25 17:50:06 ET Summary Roche Holding AG stock has seen a 13% price rise in the past month following positive trial results for its obesity treatment. Weight management and associated diseases like diabetes have huge potential, as seen from the examples of Novo Nordisk and ...

2024-06-25 13:15:54 ET More on Novo Nordisk Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk's Wegovy ge...

2024-06-25 10:45:03 ET Regis Corp. (RGS) RGS is trading UP for the last 5 days, and it at trading at $15.94 with volume of 27,015,876 and a one day change of $10.87 (214.86%). Regis Corp. has a 52-week low of 0.31 and a 52-week high of $15.24. The business's 50-day moving average pr...

2024-06-25 10:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for NVO on June 25, 2024 09:00AM ET. The previous analyst recommendation was Outperform. NVO was trading at $146.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

A look at the top 10 most actives in the United States GlycoMimetics Inc. (GLYC) rose 42.5% to $0.38 on volume of 73,016,681 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.16 on volume of 71,818,174 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 25.4% to $0.2431 on volume...

2024-06-25 09:45:00 ET It's obvious why Pfizer (NYSE: PFE) is eager to produce a medicine like Wegovy, Novo Nordisk 's (NYSE: NVO) smash-hit obesity therapy that's essentially a slightly different version of its type 2 diabetes drug called Ozempic. With such a gargantuan mar...